Use of ranolazine in long-QT syndrome type 3

Journal of Cardiovascular Electrophysiology

Volumn 19, Issue 12, 2008, Pages 1294-1295

  Kaufman, Elizabeth S ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANOLAZINE; SCN 5A PROTEIN; SODIUM CHANNEL; UNCLASSIFIED DRUG;

DIASTOLE; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DRUG INFUSION; DRUG RESEARCH; DRUG SAFETY; GENE MUTATION; HEART MUSCLE RELAXATION; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; NONHUMAN; NOTE; PRIORITY JOURNAL; QT PROLONGATION; SODIUM CURRENT; T WAVE; THERAPY EFFECT; TREATMENT RESPONSE;

ACETANILIDES; ADOLESCENT; ADULT; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; MUSCLE PROTEINS; PIPERAZINES; SODIUM; SODIUM CHANNELS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57149122526     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2008.01255.x     Document Type: Note

References (17)

1. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G : Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004 110 : 904 910.
2. Koren MJ, Crager MR, Sweeney M : Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: The Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol 2007 49 : 1027 1034.
3. Chaitman BR : Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006 113 : 2462 2472.
4. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, McCabe CH, Braunwald E : Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007 116 : 1647 1652.
5. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL : Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long QT syndrome. J Cardiovasc Electrophysiol 2008 DOI :.
6. Bennett PB, Yazawa K, Makita N, George AL Jr. : Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995 376 : 683 685.
7. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schondube FA, Tirilomis T, Tenderich G, Hasenfuss G, Belardinelli L, Maier LS : Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts - Role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008 Epub ahead of print.
8. Fredj S, Sampson KJ, Liu H, Kass RS : Molecular basis of ranolazine block of LQT-3 mutant sodium channels: Evidence for site of action. Br J Pharmacol 2006 148 : 16 24.
9. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ : Influence of genotype on the clinical course of the long-QT syndrome. International long-QT syndrome registry research group. N Engl J Med 1998 339 : 960 965.
10. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R : Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias. Circulation 2001 103 : 89 95.
11. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, Moncalvo C, Tulipani C, Veia A, Bottelli G, Nastoli J : Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004 292 : 1341 1344.
12. + channel blockade and to increases in heart rate - Implications for gene-specific therapy. Circulation 1995 92 : 3381 3386.
13. Benhorin J, Taub R, Goldmit M, Kerem B, Kass RS, Windman I, Medina A : Effects of flecainide in patients with new SCN5A mutation - Mutation-specific therapy for long-QT syndrome Circulation 2000 101 1698 1706.
14. Windle JR, Geletka RC, Moss AJ, Zareba W, Atkins DL : Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. Ann Noninvasive Electrocardiol 2001 6 : 153 158.
15. Moss AJ, Windle JR, Hall WJ, Zareba W, Robinson JL, McNitt S, Severski P, Rosero S, Daubert JP, Qi M, Cieciorka M, Manalan AS : Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): A randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol 2005 10 : 59 66.
16. Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L, Ronchetti E : The elusive link between LQT3 and Brugada syndrome - The role of flecainide challenge. Circulation 2000 102 : 945 947.
17. Antzelevitch C, Fish J : Electrical heterogeneity within the ventricular wall. Basic Res Cardiol 2001 96 : 517 527.